Monograph Details
|
|
Musculoskeletal Disorders
> Arthritis/rheumatic disorders
|
|
CELEBREX |
| Manufacturer |
|
Pfizer Labs |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
NSAID (COX-2 inhibitor). |
| Generic Name |
|
Celecoxib 50mg, 100mg, 200mg, 400mg; caps. |
| Indications |
|
Osteoarthritis (OA). Rheumatoid arthritis (RA). Ankylosing spondylitis (AS). Juvenile rheumatoid arthritis (JRA). |
| Children |
|
<2yrs: not recommended. May sprinkle capsule contents into applesauce. JRA: ≥2yrs (≥10kg to ≤25kg): 50mg twice daily; (>25kg): 100mg twice daily. |
| Adults |
|
≥18yrs: OA: 200mg once daily or 100mg twice daily. RA: 100–200mg twice daily. AS: 200mg in 1–2 divided doses; if no response after 6 weeks, 400mg once daily may be tried. <50kg: start at lowest recommended dose. |
| Contraindications |
|
Sulfonamide or aspirin allergy. 3rd trimester pregnancy. Coronary artery bypass graft surgery. |
| Precautions |
|
Advanced renal disease or severe hepatic impairment: not recommended. Renal or liver dysfunction; reduce dose by 50% in moderate hepatic insufficiency (Child-Pugh class B). Discontinue if liver disease or systemic effects (eg, eosinophilia, rash) develops. History or risk of GI bleed/ulcer (monitor). Fluid retention. Heart failure. Hypertension. Asthma. Alcoholism. Dehydrated. Elderly. Debilitated. Labor & delivery. Pregnancy (Cat.C). Nursing mothers: not recommended. |
| Interactions |
|
Caution with drugs that inhibit CYP2C9 (eg, fluconazole) or are metabolized by CYP2D6. May antagonize, or increase risk of renal failure with ACEIs, diuretics. Increased risk of GI bleed with aspirin (except low-dose), corticosteroids, smoking, anticoagulants. May potentiate lithium. Monitor warfarin. |
| Adverse Reactions |
|
GI upset/pain, edema, pharyngitis, increase AST/ALT, GI ulcer/bleed; rare: intracranial bleed, liver failure; also children: headache, fever, cough. See literature re: risk of cardiovascular events. |
| How Supplied |
Caps 100mg, 200mg—100, 500
50mg, 400mg—60 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
